Switch to:
Also traded in: Argentina, Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 7/10

vs
industry
vs
history
Cash to Debt 0.43
NYSE:CAH's Cash to Debt is ranked lower than
64% of the 50 Companies
in the Global Medical Distribution industry.

( Industry Median: 0.69 vs. NYSE:CAH: 0.43 )
Ranked among companies with meaningful Cash to Debt only.
NYSE:CAH' s Cash to Debt Range Over the Past 10 Years
Min: 0.03  Med: 0.49 Max: 1.29
Current: 0.43
0.03
1.29
Equity to Asset 0.19
NYSE:CAH's Equity to Asset is ranked lower than
86% of the 49 Companies
in the Global Medical Distribution industry.

( Industry Median: 0.40 vs. NYSE:CAH: 0.19 )
Ranked among companies with meaningful Equity to Asset only.
NYSE:CAH' s Equity to Asset Range Over the Past 10 Years
Min: 0.19  Med: 0.35 Max: 0.43
Current: 0.19
0.19
0.43
Interest Coverage 18.49
NYSE:CAH's Interest Coverage is ranked higher than
56% of the 45 Companies
in the Global Medical Distribution industry.

( Industry Median: 15.18 vs. NYSE:CAH: 18.49 )
Ranked among companies with meaningful Interest Coverage only.
NYSE:CAH' s Interest Coverage Range Over the Past 10 Years
Min: 8.62  Med: 16.98 Max: N/A
Current: 18.49
F-Score: 6
Z-Score: 4.58
M-Score: -2.42
WACC vs ROIC
6.66%
16.96%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 6/10

vs
industry
vs
history
Operating margin (%) 2.02
NYSE:CAH's Operating margin (%) is ranked lower than
66% of the 50 Companies
in the Global Medical Distribution industry.

( Industry Median: 4.22 vs. NYSE:CAH: 2.02 )
Ranked among companies with meaningful Operating margin (%) only.
NYSE:CAH' s Operating margin (%) Range Over the Past 10 Years
Min: 0.99  Med: 1.78 Max: 2.32
Current: 2.02
0.99
2.32
Net-margin (%) 1.17
NYSE:CAH's Net-margin (%) is ranked lower than
64% of the 50 Companies
in the Global Medical Distribution industry.

( Industry Median: 1.81 vs. NYSE:CAH: 1.17 )
Ranked among companies with meaningful Net-margin (%) only.
NYSE:CAH' s Net-margin (%) Range Over the Past 10 Years
Min: 0.33  Med: 1.18 Max: 2.22
Current: 1.17
0.33
2.22
ROE (%) 21.79
NYSE:CAH's ROE (%) is ranked higher than
92% of the 48 Companies
in the Global Medical Distribution industry.

( Industry Median: 9.93 vs. NYSE:CAH: 21.79 )
Ranked among companies with meaningful ROE (%) only.
NYSE:CAH' s ROE (%) Range Over the Past 10 Years
Min: 5.47  Med: 17.22 Max: 24.34
Current: 21.79
5.47
24.34
ROA (%) 4.38
NYSE:CAH's ROA (%) is ranked higher than
62% of the 50 Companies
in the Global Medical Distribution industry.

( Industry Median: 3.95 vs. NYSE:CAH: 4.38 )
Ranked among companies with meaningful ROA (%) only.
NYSE:CAH' s ROA (%) Range Over the Past 10 Years
Min: 1.33  Med: 4.49 Max: 8.29
Current: 4.38
1.33
8.29
ROC (Joel Greenblatt) (%) 109.26
NYSE:CAH's ROC (Joel Greenblatt) (%) is ranked higher than
92% of the 50 Companies
in the Global Medical Distribution industry.

( Industry Median: 22.11 vs. NYSE:CAH: 109.26 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
NYSE:CAH' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: 33.03  Med: 50.53 Max: 110.85
Current: 109.26
33.03
110.85
Revenue Growth (3Y)(%) -0.20
NYSE:CAH's Revenue Growth (3Y)(%) is ranked lower than
73% of the 41 Companies
in the Global Medical Distribution industry.

( Industry Median: 4.50 vs. NYSE:CAH: -0.20 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
NYSE:CAH' s Revenue Growth (3Y)(%) Range Over the Past 10 Years
Min: -3.2  Med: 13.55 Max: 27
Current: -0.2
-3.2
27
EBITDA Growth (3Y)(%) 8.70
NYSE:CAH's EBITDA Growth (3Y)(%) is ranked higher than
61% of the 38 Companies
in the Global Medical Distribution industry.

( Industry Median: 7.90 vs. NYSE:CAH: 8.70 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
NYSE:CAH' s EBITDA Growth (3Y)(%) Range Over the Past 10 Years
Min: -11.7  Med: 7.85 Max: 19.9
Current: 8.7
-11.7
19.9
EPS Growth (3Y)(%) 5.70
NYSE:CAH's EPS Growth (3Y)(%) is ranked lower than
69% of the 36 Companies
in the Global Medical Distribution industry.

( Industry Median: 12.00 vs. NYSE:CAH: 5.70 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
NYSE:CAH' s EPS Growth (3Y)(%) Range Over the Past 10 Years
Min: -15.7  Med: 6.4 Max: 30.9
Current: 5.7
-15.7
30.9
» NYSE:CAH's 10-Y Financials

Financials (Next Earnings Date: Est. 2016-11-02)


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow
Oprt. Cash Flow & Net Income

» Details

Guru Trades

Q3 2015

CAH Guru Trades in Q3 2015

Jim Simons 685,700 sh (New)
Joel Greenblatt 260,055 sh (+29.25%)
Vanguard Health Care Fund 6,385,231 sh (+26.61%)
John Buckingham 14,447 sh (+9.89%)
Barrow, Hanley, Mewhinney & Strauss 6,057,453 sh (-5.19%)
Keeley Asset Management Corp 114,347 sh (-6.59%)
Pioneer Investments 2,330,236 sh (-14.71%)
Ray Dalio 90,732 sh (-16.99%)
RS Investment Management 158,439 sh (-44.54%)
Paul Tudor Jones 8,700 sh (-54.20%)
» More
Q4 2015

CAH Guru Trades in Q4 2015

First Pacific Advisors 55,740 sh (New)
Steven Cohen 147,800 sh (New)
Pioneer Investments 2,483,349 sh (+6.57%)
John Buckingham 15,177 sh (+5.05%)
Vanguard Health Care Fund 6,385,231 sh (unchged)
Keeley Asset Management Corp Sold Out
Paul Tudor Jones Sold Out
Barrow, Hanley, Mewhinney & Strauss 5,845,797 sh (-3.49%)
Jim Simons 596,700 sh (-12.98%)
Ray Dalio 64,332 sh (-29.10%)
RS Investment Management 106,119 sh (-33.02%)
Joel Greenblatt 5,845 sh (-97.75%)
» More
Q1 2016

CAH Guru Trades in Q1 2016

Paul Tudor Jones 4,433 sh (New)
Jeremy Grantham 4,800 sh (New)
Leucadia National 3,700 sh (New)
Joel Greenblatt 238,494 sh (+3980.31%)
First Pacific Advisors 100,190 sh (+79.75%)
Ray Dalio 93,432 sh (+45.23%)
John Buckingham 15,829 sh (+4.30%)
Vanguard Health Care Fund 6,385,231 sh (unchged)
RS Investment Management Sold Out
Barrow, Hanley, Mewhinney & Strauss 5,838,381 sh (-0.13%)
Pioneer Investments 2,188,697 sh (-11.87%)
Steven Cohen 119,200 sh (-19.35%)
Jim Simons 67,300 sh (-88.72%)
» More
Q2 2016

CAH Guru Trades in Q2 2016

Arnold Van Den Berg 77,330 sh (New)
Scott Black 10,740 sh (New)
Paul Tudor Jones 23,853 sh (+438.08%)
Joel Greenblatt 768,372 sh (+222.18%)
Barrow, Hanley, Mewhinney & Strauss 12,520,106 sh (+114.44%)
Jim Simons 126,400 sh (+87.82%)
Ray Dalio 143,581 sh (+53.67%)
Vanguard Health Care Fund 6,385,231 sh (unchged)
Jeremy Grantham Sold Out
Leucadia National Sold Out
First Pacific Advisors 98,560 sh (-1.63%)
John Buckingham 15,551 sh (-1.76%)
Pioneer Investments 1,806,400 sh (-17.47%)
Steven Cohen 62,100 sh (-47.90%)
» More
» Details

Insider Trades

Latest Guru Trades with CAH

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Medical Distribution » Medical Distribution
Compare:NYSE:ABC, NAS:HSIC, OTCPK:SHTDF, NYSE:MCK, OTCPK:SHPMY, NAS:PDCO, NYSE:PBH, NYSE:OMI, NYSE:PMC, OTCPK:EBOSF, OTCPK:SNYR, OTCPK:ANNIF, OTCPK:NPHC, OTCPK:FZMD, OTCPK:SCVM » details
Traded in other countries:CAH.Argentina, CLH.Germany,
Cardinal Health Inc is a healthcare services company. It provides pharmaceutical & medical products & services that help pharmacies, hospitals and other healthcare providers focus on patient care. It also provides medical products to patients in the home.

Cardinal Health Inc is an Ohio corporation formed in 1979. The Company is a healthcare services company. It provides healthcare services and products for hospital systems, pharmacies, ambulatory surgery centers, clinical laboratories and physician offices. It provides clinically medical products and pharmaceuticals and cost-effective solutions that enhance supply chain efficiency from hospital to home. It connects patients, providers, payers, pharmacists, and manufacturers for integrated care coordination patient management. Its segments are pharmaceutical and medical. The Pharmaceutical segment distributes branded and generic pharmaceutical, specialty pharmaceutical, over-the-counter healthcare and consumer products in the United States. This segment also operates nuclear pharmacies and cyclotron facilities, provides pharmacy management services to hospitals as well as medication therapy management and patient outcomes services to hospitals, other healthcare providers and payers, provides services to healthcare companies supporting the development, marketing, and distribution of specialty pharmaceutical products, and repackages generic pharmaceuticals and over-the-counter healthcare products. This segment also imports and distributes pharmaceuticals, over-the-counter healthcare and consumer products as well as provides specialty pharmacy and other services in China. The Medical segment distributes a broad range of medical, surgical and laboratory products and provides services to hospitals, ambulatory surgery centers, clinical laboratories and other healthcare providers in the United States, Canada and China. This segment distributes medical products to patients in the home in the United States. This segment also manufactures, sources and develops its own Cardinal Health brand medical and surgical products, which are sold in the United States, Canada, Europe and other regions internationally. This segment also provides post-acute care management and transition services and software to hospitals, other healthcare providers and payers. The Pharmaceutical segment competes with wholesale distributors with national reach (including McKesson Corporation and AmerisourceBergen Corporation), regional wholesale distributors, self-warehousing chains, specialty distributors, third party logistics companies, companies that provide specialty pharmaceutical services and nuclear pharmacies, among others. In addition, the Pharmaceutical segment has experienced competition from a number of organizations offering generic pharmaceuticals, including telemarketers. It also competes with manufacturers that sell their products directly. The Medical segment competes with many different national medical product distributors, including Owens & Minor, Inc., Medline Industries, Inc. and McKesson Corporation. It also competes with regional medical product distributors and companies that distribute medical products to patients in the home as well as third-par

Ratios

vs
industry
vs
history
P/E(ttm) 17.98
CAH's P/E(ttm) is ranked higher than
71% of the 41 Companies
in the Global Medical Distribution industry.

( Industry Median: 22.62 vs. CAH: 17.98 )
Ranked among companies with meaningful P/E(ttm) only.
CAH' s P/E(ttm) Range Over the Past 10 Years
Min: 6.29  Med: 15.94 Max: 73.78
Current: 17.98
6.29
73.78
Forward P/E 13.77
CAH's Forward P/E is ranked higher than
67% of the 12 Companies
in the Global Medical Distribution industry.

( Industry Median: 15.04 vs. CAH: 13.77 )
Ranked among companies with meaningful Forward P/E only.
N/A
PE(NRI) 17.98
CAH's PE(NRI) is ranked higher than
68% of the 41 Companies
in the Global Medical Distribution industry.

( Industry Median: 21.78 vs. CAH: 17.98 )
Ranked among companies with meaningful PE(NRI) only.
CAH' s PE(NRI) Range Over the Past 10 Years
Min: 6.72  Med: 18.44 Max: 74.54
Current: 17.98
6.72
74.54
Price/Owner Earnings (ttm) 10.06
CAH's Price/Owner Earnings (ttm) is ranked higher than
86% of the 28 Companies
in the Global Medical Distribution industry.

( Industry Median: 27.38 vs. CAH: 10.06 )
Ranked among companies with meaningful Price/Owner Earnings (ttm) only.
CAH' s Price/Owner Earnings (ttm) Range Over the Past 10 Years
Min: 6.13  Med: 15.09 Max: 58.11
Current: 10.06
6.13
58.11
P/B 3.82
CAH's P/B is ranked lower than
83% of the 47 Companies
in the Global Medical Distribution industry.

( Industry Median: 2.16 vs. CAH: 3.82 )
Ranked among companies with meaningful P/B only.
CAH' s P/B Range Over the Past 10 Years
Min: 0.86  Med: 2.4 Max: 4.76
Current: 3.82
0.86
4.76
P/S 0.22
CAH's P/S is ranked higher than
83% of the 48 Companies
in the Global Medical Distribution industry.

( Industry Median: 1.04 vs. CAH: 0.22 )
Ranked among companies with meaningful P/S only.
CAH' s P/S Range Over the Past 10 Years
Min: 0.08  Med: 0.17 Max: 0.32
Current: 0.22
0.08
0.32
PFCF 9.40
CAH's PFCF is ranked higher than
82% of the 22 Companies
in the Global Medical Distribution industry.

( Industry Median: 19.76 vs. CAH: 9.40 )
Ranked among companies with meaningful PFCF only.
CAH' s PFCF Range Over the Past 10 Years
Min: 4.74  Med: 11.75 Max: 31.72
Current: 9.4
4.74
31.72
POCF 8.09
CAH's POCF is ranked higher than
80% of the 25 Companies
in the Global Medical Distribution industry.

( Industry Median: 12.81 vs. CAH: 8.09 )
Ranked among companies with meaningful POCF only.
CAH' s POCF Range Over the Past 10 Years
Min: 3.84  Med: 9.97 Max: 19.4
Current: 8.09
3.84
19.4
EV-to-EBIT 11.55
CAH's EV-to-EBIT is ranked higher than
71% of the 41 Companies
in the Global Medical Distribution industry.

( Industry Median: 15.77 vs. CAH: 11.55 )
Ranked among companies with meaningful EV-to-EBIT only.
CAH' s EV-to-EBIT Range Over the Past 10 Years
Min: 5.6  Med: 10.6 Max: 25.5
Current: 11.55
5.6
25.5
EV-to-EBITDA 9.30
CAH's EV-to-EBITDA is ranked higher than
80% of the 41 Companies
in the Global Medical Distribution industry.

( Industry Median: 12.40 vs. CAH: 9.30 )
Ranked among companies with meaningful EV-to-EBITDA only.
CAH' s EV-to-EBITDA Range Over the Past 10 Years
Min: 4.8  Med: 9.2 Max: 17.6
Current: 9.3
4.8
17.6
PEG 1.98
CAH's PEG is ranked higher than
57% of the 23 Companies
in the Global Medical Distribution industry.

( Industry Median: 2.10 vs. CAH: 1.98 )
Ranked among companies with meaningful PEG only.
CAH' s PEG Range Over the Past 10 Years
Min: 1.98  Med: 8.65 Max: 157.42
Current: 1.98
1.98
157.42
Shiller P/E 23.28
CAH's Shiller P/E is ranked higher than
72% of the 18 Companies
in the Global Medical Distribution industry.

( Industry Median: 35.45 vs. CAH: 23.28 )
Ranked among companies with meaningful Shiller P/E only.
CAH' s Shiller P/E Range Over the Past 10 Years
Min: 6.6  Med: 13.72 Max: 29.01
Current: 23.28
6.6
29.01
Current Ratio 1.15
CAH's Current Ratio is ranked lower than
77% of the 47 Companies
in the Global Medical Distribution industry.

( Industry Median: 1.56 vs. CAH: 1.15 )
Ranked among companies with meaningful Current Ratio only.
CAH' s Current Ratio Range Over the Past 10 Years
Min: 1.15  Med: 1.37 Max: 1.83
Current: 1.15
1.15
1.83
Quick Ratio 0.59
CAH's Quick Ratio is ranked lower than
87% of the 47 Companies
in the Global Medical Distribution industry.

( Industry Median: 1.10 vs. CAH: 0.59 )
Ranked among companies with meaningful Quick Ratio only.
CAH' s Quick Ratio Range Over the Past 10 Years
Min: 0.53  Med: 0.66 Max: 0.84
Current: 0.59
0.53
0.84
Days Inventory 32.69
CAH's Days Inventory is ranked higher than
62% of the 48 Companies
in the Global Medical Distribution industry.

( Industry Median: 46.99 vs. CAH: 32.69 )
Ranked among companies with meaningful Days Inventory only.
CAH' s Days Inventory Range Over the Past 10 Years
Min: 25.37  Med: 30.52 Max: 35.94
Current: 32.69
25.37
35.94
Days Sales Outstanding 22.24
CAH's Days Sales Outstanding is ranked higher than
86% of the 42 Companies
in the Global Medical Distribution industry.

( Industry Median: 65.41 vs. CAH: 22.24 )
Ranked among companies with meaningful Days Sales Outstanding only.
CAH' s Days Sales Outstanding Range Over the Past 10 Years
Min: 17.45  Med: 21.13 Max: 23.22
Current: 22.24
17.45
23.22
Days Payable 54.93
CAH's Days Payable is ranked lower than
61% of the 38 Companies
in the Global Medical Distribution industry.

( Industry Median: 62.84 vs. CAH: 54.93 )
Ranked among companies with meaningful Days Payable only.
CAH' s Days Payable Range Over the Past 10 Years
Min: 35.49  Med: 41.78 Max: 54.93
Current: 54.93
35.49
54.93

Dividend & Buy Back

vs
industry
vs
history
Dividend Yield 2.07
CAH's Dividend Yield is ranked higher than
65% of the 52 Companies
in the Global Medical Distribution industry.

( Industry Median: 1.59 vs. CAH: 2.07 )
Ranked among companies with meaningful Dividend Yield only.
CAH' s Dividend Yield Range Over the Past 10 Years
Min: 0.39  Med: 1.83 Max: 2.66
Current: 2.07
0.39
2.66
Dividend Payout 0.37
CAH's Dividend Payout is ranked higher than
56% of the 32 Companies
in the Global Medical Distribution industry.

( Industry Median: 0.29 vs. CAH: 0.37 )
Ranked among companies with meaningful Dividend Payout only.
CAH' s Dividend Payout Range Over the Past 10 Years
Min: 0.03  Med: 0.11 Max: 1.8
Current: 0.37
0.03
1.8
Dividend Growth (3y) 17.00
CAH's Dividend Growth (3y) is ranked higher than
76% of the 25 Companies
in the Global Medical Distribution industry.

( Industry Median: 13.60 vs. CAH: 17.00 )
Ranked among companies with meaningful Dividend Growth (3y) only.
CAH' s Dividend Growth (3y) Range Over the Past 10 Years
Min: 12.2  Med: 17 Max: 49.4
Current: 17
12.2
49.4
Forward Dividend Yield 2.31
CAH's Forward Dividend Yield is ranked higher than
63% of the 51 Companies
in the Global Medical Distribution industry.

( Industry Median: 1.89 vs. CAH: 2.31 )
Ranked among companies with meaningful Forward Dividend Yield only.
N/A
Yield on cost (5-Year) 4.18
CAH's Yield on cost (5-Year) is ranked lower than
51% of the 53 Companies
in the Global Medical Distribution industry.

( Industry Median: 4.24 vs. CAH: 4.18 )
Ranked among companies with meaningful Yield on cost (5-Year) only.
CAH' s Yield on cost (5-Year) Range Over the Past 10 Years
Min: 0.79  Med: 3.7 Max: 5.37
Current: 4.18
0.79
5.37
3-Year Average Share Buyback Ratio 1.50
CAH's 3-Year Average Share Buyback Ratio is ranked higher than
84% of the 31 Companies
in the Global Medical Distribution industry.

( Industry Median: -1.10 vs. CAH: 1.50 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
CAH' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -21.6  Med: 1.4 Max: 5.7
Current: 1.5
-21.6
5.7

Valuation & Return

vs
industry
vs
history
Price/Projected FCF 1.18
CAH's Price/Projected FCF is ranked higher than
76% of the 25 Companies
in the Global Medical Distribution industry.

( Industry Median: 1.45 vs. CAH: 1.18 )
Ranked among companies with meaningful Price/Projected FCF only.
CAH' s Price/Projected FCF Range Over the Past 10 Years
Min: 0.29  Med: 0.86 Max: 5.4
Current: 1.18
0.29
5.4
Price/Median PS Value 1.29
CAH's Price/Median PS Value is ranked lower than
71% of the 42 Companies
in the Global Medical Distribution industry.

( Industry Median: 1.00 vs. CAH: 1.29 )
Ranked among companies with meaningful Price/Median PS Value only.
CAH' s Price/Median PS Value Range Over the Past 10 Years
Min: 0.48  Med: 1.56 Max: 3.91
Current: 1.29
0.48
3.91
Price/Peter Lynch Fair Value 2.08
CAH's Price/Peter Lynch Fair Value is ranked lower than
58% of the 12 Companies
in the Global Medical Distribution industry.

( Industry Median: 2.05 vs. CAH: 2.08 )
Ranked among companies with meaningful Price/Peter Lynch Fair Value only.
CAH' s Price/Peter Lynch Fair Value Range Over the Past 10 Years
Min: 0.49  Med: 1.17 Max: 5.16
Current: 2.08
0.49
5.16
Earnings Yield (Greenblatt) (%) 8.70
CAH's Earnings Yield (Greenblatt) (%) is ranked higher than
74% of the 47 Companies
in the Global Medical Distribution industry.

( Industry Median: 5.90 vs. CAH: 8.70 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
CAH' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: 3.9  Med: 9.5 Max: 17.9
Current: 8.7
3.9
17.9
Forward Rate of Return (Yacktman) (%) 16.09
CAH's Forward Rate of Return (Yacktman) (%) is ranked higher than
62% of the 32 Companies
in the Global Medical Distribution industry.

( Industry Median: 8.81 vs. CAH: 16.09 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) (%) only.
CAH' s Forward Rate of Return (Yacktman) (%) Range Over the Past 10 Years
Min: 4.4  Med: 10.3 Max: 20.4
Current: 16.09
4.4
20.4

More Statistics

Revenue (TTM) (Mil) $121,546
EPS (TTM) $ 4.32
Beta0.84
Short Percentage of Float2.85%
52-Week Range $73.25 - 91.23
Shares Outstanding (Mil)318.59

Analyst Estimate

Jun17 Jun18
Revenue (Mil $) 131,097 140,320
EPS ($) 5.89 6.33
EPS w/o NRI ($) 5.89 6.33
EPS Growth Rate
(3Y to 5Y Estimate)
12.66%
Dividends Per Share ($) 1.65 1.73
» More Articles for NYSE:CAH

Headlines

Articles On GuruFocus.com
52-Week Company Lows Sep 15 2016 
Scott Black Bought 6 New Stocks in 2nd Quarter Aug 25 2016 
The 3 Worst Performing Dividend Aristocrats This Year Aug 25 2016 
The 10 Best Dividend Aristocrats Aug 15 2016 
Healthcare Dividend Growth Stocks: Part 1 Aug 12 2016 
Van Den Berg's Best Investments of 2nd Quarter Aug 05 2016 
Healthcare Dividend Growth Stocks: Part 1 Aug 04 2016 
Sometimes It Is Good to Buy the Biggest. But Should You Buy the Biggest Health Care Distribution Bus Jul 29 2016 
Arnold Van Den Berg 2nd Quarter: Cuts Back on Gold Miners, Gets More Bullish on Oil Jul 25 2016 
Van Den Berg Made 6 New Buys in 2nd Quarter Jul 24 2016 

More From Other Websites
Smart Access and Best Practices Inform 2017 Medicare Decisions Sep 22 2016
On Cardinal Health, Keep an Eye on $75 Sep 16 2016
Cardinal Health downgraded by Goldman Sep 16 2016
52-Week Company Lows Sep 15 2016
Nasdaq Leads, Dow Stocks Higher As Telecom Sector Heats Up Sep 14 2016
Bulls bet on bounce in Cardinal Health Sep 14 2016
Why It's Time to Buy This Year's Worst-Performing Dividend Aristocrat Stock Sep 14 2016
Startup Insurer Oscar Hires Neurosurgeon as Top Medical Officer Sep 12 2016
Cardinal Health poised to become major Navidea stockholder Sep 07 2016
Navidea Biopharmaceuticals Inc Enters into Letter of Intent with Cardinal Health for the Sale of... Sep 07 2016
Cardinal Health buying Lymphoseek from beleaguered Navidea for up to $310M Sep 06 2016
Navidea stock jumps 76% after company agrees to $80 million Cardinal Health deal Sep 06 2016
Navidea Biopharmaceuticals Enters into Letter of Intent with Cardinal Health for the Sale of... Sep 06 2016
Navidea Biopharmaceuticals Enters into Letter of Intent with Cardinal Health for the Sale of... Sep 06 2016
Cardinal Health commits to recruiting women for leadership Sep 01 2016
Cardinal Health acquisition a big win for Midwestern startup community Aug 31 2016
Fighting Prescription Drug Misuse through Community Programs: Cardinal Health Foundation Announces... Aug 31 2016
Fighting Prescription Drug Misuse through Community Programs: Cardinal Health Foundation Announces... Aug 31 2016
Rev1 Ventures lands big corporate support in launching $22M fund Aug 30 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)